Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Oct 23, 2023

BUY
$57.89 - $64.73 $781,515 - $873,855
13,500 New
13,500 $783,000
Q4 2022

Feb 02, 2023

SELL
$68.48 - $81.09 $458,816 - $543,303
-6,700 Reduced 38.95%
10,500 $755,000
Q3 2022

Nov 01, 2022

BUY
$0.13 - $76.84 $91 - $53,788
700 Added 4.24%
17,200 $1.22 Million
Q2 2022

Jul 19, 2022

BUY
$72.62 - $79.98 $806,082 - $887,778
11,100 Added 205.56%
16,500 $1.27 Million
Q1 2022

Apr 29, 2022

BUY
$61.48 - $73.72 $331,992 - $398,088
5,400 New
5,400 $394,000
Q4 2021

Jan 27, 2022

SELL
$53.63 - $62.52 $364,684 - $425,136
-6,800 Closed
0 $0
Q3 2021

Nov 04, 2021

BUY
$59.17 - $69.31 $402,356 - $471,308
6,800 New
6,800 $402,000
Q2 2021

Aug 02, 2021

SELL
$61.91 - $67.42 $916,268 - $997,816
-14,800 Closed
0 $0
Q1 2021

May 04, 2021

BUY
$59.34 - $66.74 $878,232 - $987,751
14,800 New
14,800 $934,000
Q4 2020

Feb 03, 2021

SELL
$57.74 - $65.43 $964,258 - $1.09 Million
-16,700 Closed
0 $0
Q3 2020

Nov 10, 2020

BUY
$57.43 - $63.64 $959,081 - $1.06 Million
16,700 New
16,700 $1.01 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $126B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Toews Corp Portfolio

Follow Toews Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Toews Corp , based on Form 13F filings with the SEC.

News

Stay updated on Toews Corp with notifications on news.